首页> 美国卫生研究院文献>other >Role of the DECAF Score in Predicting In-hospital Mortality in Acute Exacerbation of Chronic Obstructive Pulmonary Disease
【2h】

Role of the DECAF Score in Predicting In-hospital Mortality in Acute Exacerbation of Chronic Obstructive Pulmonary Disease

机译:DECAF评分在预测慢性阻塞性肺疾病急性加重期间住院死亡率的作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

IntroductionAcute exacerbations of chronic obstructive pulmonary disease (AECOPD) can be fatal. In 2012, a comprehensive score was developed to predict the risk of in-hospital mortality in AECOPD called the dyspnoea, eosinopenia, consolidation, acidemia, and atrial fibrillation (DECAF) score. We conducted this study to assess the value of the DECAF score as a clinical prediction tool that claims to stratify all patients with AECOPD by risk accurately.MethodsWe conducted a prospective study of patients admitted to the intensive care unit (ICU) of the Department of Pulmonology in Civil Hospital, Jamshoro, from January 2016 to December 2018. Our inclusion criteria were that the patient must be age 35 years or older, have a primary clinical diagnosis of AECOPD, spirometry consistent with airflow obstruction, and have a smoking history of ≥10 cigarette pack per year. We excluded patients who had domiciliary ventilation, survival-limiting comorbidities (such as metastatic malignancy), and a primary reason for admission other than AECOPD. All sociodemographic data were collected at the time of admission, including age, gender, co-morbidities, housebound status, and number of previous AECOPD. Clinical data collected included plain chest x-ray, spirometry, electrocardiogram, arterial blood gases analysis, complete blood count, kidney function test, liver function test, and serum electrolytes. A DECAF score was applied to each patient. We noted in-hospital mortality and compared the characteristics of survivors and non-survivors. Data were analyzed using IBM SPSS for Windows, version 19.0 (IBM Corp, Armonk, NY).ResultsA total of 162 patients were included in the study. The mortality rate was 13% (n=21). More survivors had a DECAF score from zero to three than non-survivors. The difference in the number of survivors vs. non-survivors was statistically significant for DECAF scores zero and one. For DECAF scores four and five, there were more patients in the “non-survivors” group, and the differences were statistically significant. None of the patients scored six on DECAF.ConclusionPatients with a DECAF score of four or higher have a significant risk of mortality. DECAF is a simple tool that predicts mortality that incorporates routinely available indices to stratify AECOPD patients into mortality risk categories.
机译:简介慢性阻塞性肺疾病(AECOPD)的急性加重可能是致命的。 2012年,开发了一项综合评分来预测AECOPD的院内死亡风险,称为呼吸困难,曙红减少症,巩固,酸血症和心房颤动(DECAF)评分。我们进行了这项研究,以评估DECAF评分作为一种临床预测工具的价值,该工具声称可以通过风险准确地对所有AECOPD患者进行分层。方法我们对肺科重症监护病房(ICU)的患者进行了前瞻性研究在2016年1月至2018年12月期间在Jamshoro市民医院就诊。我们的纳入标准是患者必须年满35岁,对AECOPD进行主要临床诊断,肺活量与气流阻塞相符,并且吸烟史≥10每年烟盒。我们排除了有住所通气,生存受限的合并症(如转移性恶性肿瘤)和除AECOPD以外的主要入院原因的患者。入院时收集了所有社会人口统计学数据,包括年龄,性别,合并症,房屋状况和以前的AECOPD数量。收集的临床数据包括胸部X线平片,肺活量测定,心电图,动脉血气分析,全血细胞计数,肾功能检查,肝功能检查和血清电解质。将DECAF评分应用于每位患者。我们记录了院内死亡率,并比较了幸存者和非幸存者的特征。使用适用于Windows的IBM SPSS 19.0版(IBM Corp,Armonk,NY)对数据进行分析。结果研究共纳入162名患者。死亡率为13%(n = 21)。 DECAF得分从零到三分的幸存者比非幸存者多。 DECAF评分为零和一时,幸存者与非幸存者的数量差异具有统计学意义。对于DECAF评分4和5,“非幸存者”组中的患者更多,差异具有统计学意义。 DECAF评分中没有一个患者得分为6。结论DECAF评分为4或更高的患者有明显的死亡风险。 DECAF是一种简单的预测死亡率的工具,该工具结合了常规可用指标,将AECOPD患者分为死亡风险类别。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号